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Abstract
Background: Cytomegalovirus (CMV) viremia has been shown to be an independent risk factor for increased mortality
among HIV-infected individuals in the developing world. While CMV infection is nearly ubiquitous in resource-poor settings,
few data are available on the role of subclinical CMV reactivation on HIV.
Methods: Using a cohort of mineworkers with stored plasma samples, we investigated the association between CMV DNA
concentration and mortality prior to antiretroviral therapy availability.
Results: Among 1341 individuals (median CD4 count 345 cells/ml, 70% WHO stage 1 or 2, median follow-up 0.9 years), 70
(5.2%) had CMV viremia at baseline; 71 deaths occurred. In univariable analysis CMV viremia at baseline was associated with
a three-fold increase in mortality (hazard ratio [HR] 3.37; 95% confidence intervals [CI] 1.60, 7.10). After adjustment for CD4
count, WHO stage and HIV viral load (N= 429 with complete data), the association was attenuated (HR 2.27; 95%CI 0.88,
5.83). Mortality increased with higher CMV viremia ($1,000 copies/ml vs. no viremia, adjusted HR 3.65, 95%CI: 1.29, 10.41).
Results were similar using time-updated CMV viremia.
Conclusions: High copy number, subclinical CMV viremia was an independent risk factor for mortality among male HIV-
infected adults in South Africa with relatively early HIV disease. Studies to determine whether anti-CMV therapy to mitigate
high copy number viremia would increase lifespan are warranted.
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Introduction
Cytomegalovirus (CMV) is a major opportunistic pathogen
among HIV-infected persons. Not only is it important because of
its direct pathogenicity leading to CMV end-organ disease and
death in severely immunosuppressed individuals, typically those
with CD4 cell counts of less than 100 cells/ml[1,2], but also
because of its potential role in HIV disease progression [3,4].
Since the 1980s, a number of studies investigated the association
between CMV and mortality among HIV-infected individuals.
However, most early studies used CMV antibody positivity as the
exposure of interest[5,6,7]. Quantification of CMV viremia is a
more precise marker of CMV activity and more recent studies
have used this as the exposure of interest[8,9,10,11,12,13], but
many of these have been in cohorts receiving antiretroviral
therapy (ART), among whom it is more difficult to tease out the
effect of CMV on natural history of HIV infection. Most persons
who are CMV antibody positive harbour latent rather than active
CMV infection. As such, virological markers of ongoing CMV
replication are likely to be more accurate predictors of the
association between CMV reactivation and HIV mortality.
Subclinical CMV infection is a well known risk factor for mortality
in organ and bone marrow transplant recipients[14,15].
Between 1999 and 2002 we conducted a cohort study[16]
among employees of a gold mine in South Africa attending a
newly-established HIV clinic, prior to the availability of ART; as
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part of this study, serial blood samples were stored. This created an
opportunity to investigate the effect of CMV viremia on mortality
in this cohort.
Methods
Ethical statement
The study was approved by Research Ethics Committees of the
University of KwaZulu Natal, South Africa; the London School of
Hygiene and Tropical Medicine, UK; and the Institutional
Review Board of the Fred Hutchinson Cancer Research Center,
Seattle, USA.
Study design, population and data collection
This analysis used data from a workplace HIV clinic within a
large gold mining company in the Free State Province, South
Africa, in the context of a prospective cohort study (the "parent
study") to explore the effect of tuberculosis on HIV viral load
between May 1999 and March 2002[16]. The clinic was
administered by the company and provided employees with free,
comprehensive health care. In 1999, specialized care for HIV-
infected employees was added[17]. Voluntary counselling and
testing for HIV infection was encouraged for persons with a
sexually transmitted infection, or tuberculosis; persons testing HIV
positive were invited to the clinic. All patients were screened for
active tuberculosis at clinic entry and offered isoniazid preventive
therapy if they had no evidence of active tuberculosis or history of
prior tuberculosis treatment, and cotrimoxazole preventive
therapy if the CD4 count was below 200 cells/ml, or if they had
symptomatic HIV disease and a CD4 count below 250 cells/ml.
Patients were seen for routine follow up every six months. As part
of routine clinic procedures, at every visit, data were collected on
demographic and medical history, physical examination, World
Health Organization (WHO) disease stage, and clinical laboratory
analyses including measurement of CD4 cell count. Neither ART
nor quantification of HIV load was routinely available at the time
of the study.
Clinic patients who were 18 years of age or older were invited to
enrol in the parent study, regardless of CD4 cell count, and for
those consenting, plasma samples obtained at routine visits were
stored. All participants in the parent study who had stored plasma
available for testing for CMV and who had a CD4 count available
within 6 six months of their first (defined as ‘‘baseline’’) stored
plasma sample were eligible for this analysis. Mortality informa-
tion was obtained from medical and employment records. Because
CMV infection is ubiquitous amongst adults in developing
countries[18], we did not test for CMV antibodies. Stored plasma
from all samples available for each participant were analysed
retrospectively at the University of Washington for CMV DNA in
a previously validated assay. HIV RNA concentration was
measured at baseline on all subjects with CMV viremia and on
a randomly selected subset of participants without CMV viremia,
using the same plasma sample as the baseline CMV measurement.
Laboratory methods
DNA was extracted from 200 ul of stored plasma and eluted
into 100 ul of AE buffer (Qiagen Inc). Ten ul of DNA was then
analyzed by CMV specific TaqMan real-time PCR as previously
described[19]. The lower limit of detection of CMV DNA was
50 copies/ml. HIV-1 particles were pelleted by centrifugation
from 500 ml plasma. RNA was extracted from the pellet and
resuspended in 50 ul of AE buffer. Twenty ul of RNA was then
used to detect HIV RNA by real-time RT- PCR as described
previously[20].
Statistical analysis
The chi-square test or Fisher’s exact test, and Wilcoxon rank
sum test were used to assess the association of categorical and
quantitative variables, respectively, with baseline CMV viremia.
The primary outcome for this analysis was death. Participants
were considered to enter the cohort on the date of the first
available CMV measurement (baseline), and were followed until
death, leaving the work force, or end of study (31st March 2002),
whichever came first. CD4 count and WHO stage at baseline were
defined as the closest measurement, within 6 six months, to the
date of the baseline CMV measurement.
Cox proportional hazards regression was used to estimate the
effect of baseline CMV viremia on time to death. Data were
reported as hazard ratios (HRs), 95% confidence intervals (CIs),
and P values from the likelihood ratio test (LRT). CMV viremia
status was defined as positive (.50 copies/ml) or negative and as a
variable on three levels (negative, 51–999, $1000 copies/ml).
Where appropriate, tests for linear trend and departures from
linear trend were assessed using the LRT. Non-proportional
hazards for CMV and other factors were explored. A multivar-
iable analysis was conducted to assess the relationship between
CMV viremia and death, controlling for potential confounders
including age, CD4 cell count and WHO stage. An interaction
between CD4 cell count (,200 versus $200 cells/ml) and CMV
viremia was defined a priori and was assessed using the LRT. The
analysis was repeated on a subset of individuals with data on HIV
RNA concentration. Time to death by CMV viremia status
measured at baseline was summarized graphically by Kaplan-
Meier survival curves, stratified by CD4 count (,200 and
$200 cells/ml) at baseline.
A sensitivity analysis was conducted using all available CMV
measurements during follow-up, therefore modelling CMV
viremia as a time-updated covariate.
Data were analysed using STATA v. 10 (Stata Corporation,
College Station, Texas, USA).
Results
Baseline characteristics and CMV status
Between May 1999 and March 2002, 1,342 patients were
enrolled in the parent study, and had suitable stored specimens
available for analysis for CMV viremia. One patient had missing
baseline WHO stage, and so analysis was restricted to 1,341
patients. The population was predominantly male (1,335; 99.6%)
with a median age of 39 (range 19–59) years, consistent with the
demographics of the gold mining workforce (table 1). The median
baseline CD4 cell count was 345 cells/ml (interquartile range
[IQR]: 218–508), 29% had a previous episode of TB and 70%
(934) were in WHO stage 1 or 2 (table 1). None were receiving
ART.
The median number of CMV measurements per patient,
including the baseline sample, was two (range one to nine) with a
total of 2703 measurements overall. Including all measurements,
146 participants (10.9%) had at least one sample with detectable
CMV viremia. Of the 770 participants with at least two
measurements, 84.3% (649) were consistently negative (median
of two measurements), 1.4% (11) consistently positive (median of
two measurements) and 14.3% (110) had their CMV viremia
status change at least once during follow-up (median of three
measurements). The median time between the first and second
measurement was 6.6 months. Of participants with a baseline
CD4 count$200 cells/ml, by 6 months 89.5% (453/506) main-
tained a CD4$200, with a median decrease of 26 cells/ml (IQR
26–86) over that period.
CMV Viremia, HIV and Mortality in South Africa
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Of the 1,341 patients, 70 (5.2%) had detectable CMV viremia
at baseline with a median CMV DNA level of 524 copies/ml
(IQR: 116–1994) and 40% of those had CMV DNA level
$1000 copies/ml. Those with detectable CMV viremia had a
lower median CD4 cell count (213 vs. 354 cells/ml, p,0.0001),
higher HIV RNA concentration (47.1% vs. 27.6% with $5log10
copies/ml, p,0.0001) and a higher proportion were in WHO
stage 3 or 4 (43% vs. 30%, p= 0.001), compared to those without
CMV viremia (table 1).
Association of baseline CMV viremia and time-updated
CMV viremia with mortality
The median follow-up time was 0.9 years (range 0.01–2.3) with
a total of 1,534 person years of observation, during which 71
deaths occurred. In unadjusted analysis, CMV viremia at baseline
was associated with a greater than three-fold increased hazard of
death (unadjusted HR 3.37; 95% CI 1.60, 7.10; P= 0.006, table 2).
After adjusting for CD4 cell count and WHO stage, the HR was
substantially attenuated to 1.17 (95% CI 0.52, 2.65; P= 0.71).
Kaplan-Meier survival curves for CMV viremia at baseline,
stratified by CD4 count (,200 and $200 cells/ml) are shown in
figure 1. Age did not confound the association, and was therefore
not included in the model. There was no evidence for an
interaction between CD4 group (,200,$200 cells/mL) and CMV
viremia (P= 0.87). In the unadjusted analysis there was a trend for
increasing mortality risk with increasing levels of CMV viremia (P
for trend 0.002), though after adjustment only those with
$1000 copies/ml had evidence of an increased hazard of death
(adjusted HR 2.02, 95% CI 0.78–5.27) compared to those without
CMV viremia.
Results were similar for the sensitivity analysis when CMV
viremia was time-updated using all available CMV viremia
measurements in follow-up (table 2). The unadjusted HR for
mortality comparing those with versus without CMV viremia was
3.52 (95% CI 1.89, 6.55; P,0.001) and after adjustment for
baseline CD4 cell count and WHO stage the HR was 1.25 (95%
CI 0.63, 2.47; P= 0.53). However, for those with CMV viremia
$1000 copies/ml versus those without CMV viremia, the
unadjusted and adjusted HRs were 8.13 (95% CI 4.02, 16.32)
and 2.85 (95% CI 1.35, 6.02), respectively, indicating that the
development of high copy number CMV plasma viremia was an
independent risk factor for increased mortality.
Analysis restricted to 429 patients with HIV RNA concentration
data (27 deaths) showed consistent evidence of an increased hazard
of death for those with CMV viremia at baseline after adjustment
for CD4 cell count, WHO stage and HIV viral load (adjusted HR
2.27, 95% CI 0.88, 5.83, p= 0.11). There was again no evidence
for an interaction between CD4 group (,200, $200 cells/ml) and
CMV viremia defined as positive or negative (P= 0.71). For CMV
viremia defined on three levels, after adjustment, increased
mortality was observed with with increasing levels of CMV
viremia (P for trend 0.04); those with $1000 copies/ml had an
adjusted HR of 3.65 (95% CI 1.29, 10.41) compared to being
CMV negative. Results were similar for the analysis based on
time-updated CMV viremia (data not shown).
Discussion
This retrospective laboratory evaluation of a prospective cohort
study of HIV-infected sub-Saharan African men found a
consistent association between CMV viremia, especially high copy
Table 1. Description of cohort overall, and stratified by CMV viremia at baseline.
All participants
CMV viremia: .50 copies/
ml a Negative for CMV viremia P valueb
(n =1341) (n =70) (n =1271)
Age (years) Median (IQR) 39 (35–45) 40 (36–46) 39 (35–44) 0.33
CD4 count (cells/mL) Median (IQR) 345 (218, 508) 213 (108–318) 354 (225–517) ,0.0001
n (col %) n (col %) n (col %)
Sex Male 1335 (99.6) 70 (100) 1265 (99.5) .0.99
CD4 count (cells/mL) ,100 83 (6.2) 16 (22.9) 67 (5.3) ,0.0001
100–199 196 (14.6) 15 (21.4) 181 (14.2)
200–349 401 (29.9) 26 (37.1) 375 (29.5)
$350 661 (49.3) 13 (18.6) 648 (51.0)
WHO stage 1 or 2 934 (69.6) 41 (58.6) 893 (70.3) 0.001
3 328 (24.5) 18 (25.7) 310 (24.4)
4 79 (5.9) 11 (15.7) 68 (5.4)
HIV viral loadc (log10
copies/ml)
,4 139 (32.4) 9 (12.9) 130 (36.2) ,0.0001
4–5 158 (36.8) 28 (40.0) 130 (36.2)
$5 132 (30.8) 33 (47.1) 99 (27.6)
Previous tuberculosis Yes 393 (29.3) 30 (42.9) 363 (28.6) 0.01
an = 42 and n = 28 have CMV DNA levels of between 51–999 and $1000 copies/ml, respectively;
bcomparing CMV viremia versus no viremia at baseline using chi-square test or Fisher’s exact test for categorical variables and the Wilcoxon rank sum test for
quantitative variables;
cn = 429 with HIV viral load data
IQR: interquartile range; col = column; WHO stage =World Health Organization HIV clinical stage.
doi:10.1371/journal.pone.0025571.t001
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levels of CMV DNA in plasma, and increased hazard of death.
These data are unusual in that they come from a population of
miners in South Africa, many of whom had not reached the stage
of advanced HIV disease, and in this context suggest that the
association between CMV and mortality is not restricted to
individuals with advanced HIV-related disease or those with overt
CMV end-organ damage.
The prevalence at baseline of CMV viremia in our study, at 5%,
was somewhat lower than has been reported in other stud-
ies[10,12,21,22], despite using an assay which could detect CMV
viremia at concentrations of 50 copies/ml. Whether this is a true
biological phenomenon, or the difference between serum and
plasma will require more detailed evaluation. Overall, 11% of
patients had at least one specimen with detectable CMV viremia.
This is consistent with the relatively high median CD4 count
among our participants. Our data contribute to the very limited
information concerning the prevalence of CMV viremia among
people with HIV infection in resource-limited settings. In a small
study of pregnant women in Kenya, 17% had CMV viremia; the
median CD4 count was 335 cells/ml among those with CMV
viremia and 420 cells/ml among those without[21]; post-partum
survival was shorter among women with CMV viremia. Among
377 adults newly-diagnosed with HIV infection in Cambodia,
55.2% had CMV viremia; this very high prevalence may be
explained by the group being severely immunosuppressed with a
median CD4 count of 30 cells/ml[22].
Studies in the U.S. and Europe among patients on ART have
also found associations between CMV viremia and increased risk
of death, with hazard ratios ranging from nearly 2 to almost 5 after
controlling for other indicators of disease progression such as CD4
Table 2. Effect baseline and time-updated CMV viremia on mortality, unadjusted and adjusted hazard ratios from Cox
proportional hazards regression, 95% confidence intervals and P values (n = 1341).
Deaths/
pyrs
Rate/ 100
pyrs
Unadjusted
HR
Model a: Adjusted
HRa (95% CI)
Model b: Adjusted
HRa (95% CI)
Model c: Adjusted
HRa (95% CI)
Model d: Adjusted
HRa (95% CI)
(Baseline CMV viremia) (Time-updated CMV viremia)
CMV viremia at
baseline
(copies/ml)
-ve 63/1475 4.3 1 (p = 0.006) 1 (p = 0.71) N/A N/A N/A
.50 8/59 13.5 3.37 1.17 (0.52–2.65)
CMV viremia at
baseline
(copies/ml)
-ve 63/1475 4.4 1 (p = 0.006b) N/A 1 (p = 0.28) N/A N/A
51-999 3/38 7.8 1.96 0.65 (0.19-2.24)
$1000 5/21 23.9 5.99 2.02 (0.78–5.27)
CMV viremia
time-updated
(copies/ml)
-ve 59/1451 4.1 1 (p,0.001) N/A N/A 1 (p = 0.53) N/A
.50 12/83 14.4 3.52 1.25 (0.63–2.47)
CMV viremia
time-updated
(copies/ml)
-ve 59/1451 4.1 1 (p,0.001c) N/A N/A N/A 1 (p = 0.009)
51–999 3/55 5.5 1.30 0.45 (0.14–1.49)
$1000 9/28 31.9 8.13 2.85 (1.35, 6.02)
CD4 count d
(cells/mL)
,100 26/60 43.2 81.4 64.1 (23.5–175) 64.8 (23.8–176) 62.6 (22.9–171) 64.7 (23.6–177)
100–199 24/211 11.4 18.3 16.4 (6.23–43.4) 15.9 (6.00–42.0) 16.4 (6.19–43.2) 16.1 (6.10–42.6)
200–349 16/481 3.3 5.19 4.88 (1.78–13.4) 4.90 (1.79–13.4) 4.85 (1.77–13.3) 4.78 (1.75–13.1)
$350 5/782 0.6 1 (p,0.001) 1 (p,0.001) 1 (p,0.001) 1 (p,0.001) 1 (p,0.001)
WHO stage 1–2 32/1121 2.8 1 (p,0.001) 1 (p = 0.16) 1 (p = 0.13) 1 (p = 0.18) 1 (p = 0.17)
3 29/340 8.5 3.04 1.62 (0.96–2.73) 1.65 (0.98–2.78) 1.61 (0.96–2.71) 1.61 (0.96–2.71)
4 10/73 13.7 5.08 1.58 (0.72–3.49) 1.70 (0.78–3.71) 1.54 (0.71–3.38) 1.57 (0.72–3.46)
Age (years) ,35 9/394 2.3 1 (p = 0.1) Not adjusted for Not adjusted for Not adjusted for Not adjusted for
35–39 26/436 6.0 2.62
40–44 18/353 5.1 2.23
45–49 13/246 5.3 2.43
$50 5/105 4.8 2.14
aadjusted for all variables shown; P value shown in parentheses;
bP-value for trend = 0.002;
cP-value for trend,0.001;
dCD4 categories are ,100, 100-199, 200-349 and $350 cells/mL.
pyrs = person years; HR = hazard ratio; CI = confidence interval; -ve = negative; N/A = not applicable; WHO stage =World Health Organization HIV clinical stage.
doi:10.1371/journal.pone.0025571.t002
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cell count and HIV viral load[10,11,12,13]. Some studies have
reported that the risk of death has a linear association with the
log10 CMV DNA concentration. Bowen et al. and Spector et al.
reported that each log10 increase in CMV DNA load was
associated with a 1.9-fold and 2.2-fold increase in mortality,
respectively[12,13]. Among adults in Cambodia, Micol et al. found
that CMV viral load greater than 3.1log10 copies/ml was
independently associated with death[22]. To our knowledge, this
is the first study of persons in sub-Saharan Africa with relatively
high CD4 counts showing an independent association between
high copy numbers of CMV viremia and subsequent mortality.
Assessment of causality is difficult in studies such as ours, and
thus we cannot determine whether higher CMV viremia directly
increases the risk of death, or whether it is a marker of higher
mortality risk attributable, for example, to impaired immune
function, independent of the CD4 count. However a randomised
trial of CMV-specific therapy would be needed to address this
question, most likely in addition to antiretroviral therapy. A cohort
study conducted in the US, found that treatment with systemic
anti-CMV treatment was associated with a 28% reduction in
mortality amongst patients with CMV retinitis, independent of
HAART and using time-updated covariates [23]. Overall,
however, data documenting the cofactor effect of CMV on HIV
disease progression are accumulating[3]. In addition, the delete-
rious effect of CMV viremia in persons with a higher CD4 count,
who are not candidates for antiretroviral therapy according to
current guidelines for resource-poor countries, suggests that CMV
diagnostics and therapeutics should be considered for evaluation in
these settings.
Our study has some limitations. First, although we had a large
cohort of 1,342 participants, only a subset had data on HIV RNA.
In the multivariable analysis, the association between CMV and
mortality was stronger after adjusting for HIV RNA load,
suggesting negative confounding. This observation is consistent
with the hypothesis that the mechanism of action of CMV on risk
of death is independent of its action on plasma HIV RNA[3].
Second, our cohort was not treated with antiretroviral therapy,
limiting the ability to generalize the findings to patients receiving
current standard of care treatment. Since 2003 goldminers have
had access to ART, free-of-charge. Earlier initiation of ART, as
per current guidelines in South Africa, is likely to be beneficial in
reducing mortality, including that related to CMV. Anti-CMV
interventions for those with higher CD4 counts could be worth
exploring.
In summary, we found associations between CMV viremia and
increased risk of death in a population of gold miners with HIV
infection, but mostly without advanced immunosuppression, prior
to the ART era. Earlier initiation of ART, as per current
guidelines in South Africa, may be helpful in reducing mortality.
Further research on interventions to prevent high copy number
subclinical CMV viremia may be warranted.
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